Last reviewed · How we verify
Oroxid®
Oroxid is an oral anticoagulant that inhibits Factor Xa in the coagulation cascade to prevent thrombus formation.
Oroxid is an oral anticoagulant that inhibits Factor Xa in the coagulation cascade to prevent thrombus formation. Used for Thromboembolism prevention and treatment.
At a glance
| Generic name | Oroxid® |
|---|---|
| Also known as | 3% hydrogen peroxide mouthwash |
| Sponsor | Charles University, Czech Republic |
| Drug class | Direct Factor Xa inhibitor |
| Target | Factor Xa |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Oroxid is a direct Factor Xa inhibitor, a class of anticoagulants that selectively blocks Factor Xa, a key enzyme in the intrinsic and common pathways of blood coagulation. By inhibiting Factor Xa, it prevents the generation of thrombin and subsequent fibrin clot formation, reducing thrombotic risk. It is administered orally and has been developed for prevention and treatment of thromboembolic disorders.
Approved indications
- Thromboembolism prevention and treatment
Common side effects
- Bleeding
- Gastrointestinal disturbances
Key clinical trials
- Assessment of the Efficacy and Safety of OROXID® Oral Solution in Patients With Gingivitis (NA)
- Assessment of the Efficacy and Safety of OROXID® Oral Solution in Patients With Periodontitis (NA)
- Assessment of the Efficacy and Safety of OROXID® Oral Solution in Patients With Oral Cavity Surgery (NA)
- Oral Care With 3% Hydrogen Peroxide (Oroxid®) in ICU - Effects on the Lower Airway Microbial Colonisation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oroxid® CI brief — competitive landscape report
- Oroxid® updates RSS · CI watch RSS
- Charles University, Czech Republic portfolio CI